Grupo de Bioinformática e prospecção molecular, Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
Auto-generated profile, based on publicly available information
Thaysa Walléria de Aragão Santos
Grupo de Bioinformática e prospecção molecular, Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
Metabolic syndrome includes several diseases that are associated with metabolic abnormalities such as obesity, dyslipidemia, hypertension, type 2 diabetes, obesity, cardiac diseases, and insulin resistance. In order to maintain cellular homeostasis, it is necessary to regulate the signaling pathways involved in controlling oxidative stress. Nuclear factor erythroid-2 factor 2 (NRF2) is a transcription factor largely expressed in several tissues and cells and participates in the oxidative stress regulation signaling pathways. NRF2 also mediates transcriptional regulation of a variety of target genes to signalize and regulate acute and chronic stress pathways in metabolic syndrome. Deregulation of NRF2 could contribute to a worst prognosis/profile of individuals with metabolic syndrome. Therefore, NRF2 and its activators might play a role in its treatment, highlighted as targets for modulation by pharmacological agents.